Skip to main content
CREO MEDICAL GROUP PLC logo

CREO MEDICAL GROUP PLC — Investor Relations & Filings

Ticker · CREO ISIN · GB00BZ1BLL44 LEI · 213800H188ZDCWWXFA21 IL Manufacturing
Open in API
Filings indexed 317 across all filing types
Latest filing 2026-05-22 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL CREO

About CREO MEDICAL GROUP PLC

https://www.creomedical.com/

Creo Medical Group PLC is a medical device company specializing in the development and commercialization of minimally invasive electrosurgical devices for therapeutic endoscopy. The company's core technology platform integrates advanced bipolar radiofrequency for precise tissue cutting with high-frequency microwave energy for controlled coagulation. Its principal products, such as the Speedboat device, are designed to enable clinicians to perform complex procedures like endoscopic submucosal dissection (SSD) to remove gastrointestinal lesions. By providing alternatives to traditional surgery, Creo Medical aims to improve patient outcomes, reduce recovery times, and lower healthcare costs. The company also provides extensive clinical education and training programs to support healthcare professionals in adopting its advanced energy technologies.

Recent filings

Filing Released Lang Actions
Result of Placing
Share Issue/Capital Change Classification · 95% confidence The document is an RNS announcement from Creo Medical Group plc dated 22 May 2026 announcing the result of a placing (subscription) of 36,666,664 new ordinary shares to raise £5.5m. It provides detailed terms of the share issue, admission to trading, total voting rights, and directors’ participation. This is clearly a share issuance/capital change announcement rather than a full financial report or earnings release. It therefore falls under the “Share Issue/Capital Change” category (Code: SHA).
2026-05-22 English
FY25 Final Results
Earnings Release Classification · 90% confidence The document is an RNS announcement titled “FY25 Final Results” for the year ended 31 December 2025. It provides key financial highlights (revenue, operating loss, cash, disposal proceeds), product and operational updates, and outlook commentary by the CEO. This is a first‐release of audited final financial results rather than the full annual report itself, fitting the definition of an Earnings Release (initial announcement of periodical financial results). FY 2025
2026-05-22 English
Proposed Placing to raise approximately £5.5m
Capital/Financing Update Classification · 95% confidence The document is a long regulatory announcement describing a proposed placing of new ordinary shares to raise approximately £5.5 million, details of the bookbuild, director subscriptions, use of proceeds, and convertible loan notes. It constitutes a fundraising and capital structure update rather than a full financial report, dividend notice, board change, or merger document. Therefore it falls under the Capital/Financing Update category (CAP).
2026-05-22 English
Proposed Sale of 49% Interest in Creo Medical SL
M&A Activity Classification · 85% confidence The document is an RNS announcement under UK MAR in which Creo Medical Group plc describes a proposed sale of its 49% shareholding in its European subsidiary. It provides transaction terms (enterprise value, consideration, conditions precedent) and states that a further announcement will follow. This is a corporate disposal transaction announcement rather than a periodic report, fundraising notice, or regulatory certification. It therefore fits the definition of an M&A Activity announcement (Code: TAR).
2026-05-22 English
MicroBlate™ Fine commercial update
Regulatory Filings Classification · 95% confidence The document is a press release from Creo Medical Group plc dated 07 May 2026, providing a commercial and clinical update on their MicroBlate Fine product. It discusses clinical adoption, commercial rollout, and early case results but does not contain financial statements, detailed financial analysis, or regulatory filings. It is not an earnings release or annual/interim report. The content is focused on product and commercial progress rather than financial results or governance. The document is a typical regulatory news service (RNS) announcement providing company updates that do not fit into more specific categories like earnings, capital changes, or management changes. Therefore, the best classification is Regulatory Filings (RNS).
2026-05-07 English
SpydrBlade™ Flex used in novel BEAM procedures
Regulatory Filings Classification · 95% confidence The document is a press release announcing the clinical use of a medical device (SpydrBlade Flex) in a novel bariatric endoscopic technique by a leading US innovator. It contains no financial data, no regulatory filings, no voting results, no management changes, no earnings or financial reports, and no legal or merger information. The document is informational and promotional in nature, typical of a Regulatory Filing (RNS) which serves as a general announcement that does not fit into other specific categories. The document length is 7934 characters, which is sufficient for a full report but the content is clearly a news announcement rather than a financial or regulatory report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-05-05 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.